You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 15, 2026

Profile for Mexico Patent: 2021014126


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Mexico Patent: 2021014126

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial May 20, 2040 Amgen Inc LUMAKRAS sotorasib
⤷  Start Trial May 20, 2040 Amgen Inc LUMAKRAS sotorasib
⤷  Start Trial May 20, 2040 Amgen Inc LUMAKRAS sotorasib
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Patent MX2021014126: Scope, Claims, and Landscape

Last updated: February 20, 2026

Overview
Patent MX2021014126, filed in Mexico, covers a pharmaceutical compound or formulation. Its scope primarily focuses on a specific chemical entity or a therapeutic application, with claims designed to establish exclusivity over its use and synthesis. Its landscape reveals positioning within the Mexican and international patent systems, reflecting strategic priorities of the applicant(s) relative to competitors.

Patent Scope and Claims

Claim Structure
The patent's claims are categorized into independent and dependent claims. The independent claim outlines the core invention—likely a novel compound, a specific pharmaceutical composition, or a method of treatment. Dependent claims specify particular embodiments such as dosage forms, delivery routes, or combination therapies.

Example of Typical Claim Language

  • Independent claim: "A pharmaceutical composition comprising compound X or a pharmaceutically acceptable salt, wherein the compound exhibits activity against disease Y."
  • Dependent claims: "The composition of claim 1, further comprising a carrier or excipient," or "The composition of claim 1, wherein the compound is administered orally."

Claims Analysis

  • The scope centers on chemical novelty and therapeutic utility.
  • Claims specify the novel compound's structural formula, stereochemistry, or combination with known agents.
  • The claims likely include methods of synthesis, further expanding patent breadth.

Limitations

  • If claims are narrowly defined around a specific compound or dosage, they may be vulnerable to design-around strategies.
  • Broad claims risk invalidation through prior art references that disclose similar compounds or methods.

Prior Art and Patent Landscape

Global Patent Activity

  • Similar compounds may be protected under patents in the US, EU, China, or other jurisdictions.
  • Patent families often include filings in multiple countries to secure global exclusivity.
  • International applications might be based on PCT filings, extending protection prospects.

Mexican Patent Environment

  • Mexico's patent laws are aligned with international standards, emphasizing novelty, inventive step, and industrial applicability (IMPI, 2020).
  • Examination focuses on chemical and pharmaceutical novelty, with searches extending to prior art in Latin America and globally.

Key Competitors

  • Companies like Novartis, Pfizer, or local firms may hold related patents.
  • Competitor patents often cover similar molecular targets, combination therapies, or delivery systems.

Patent Term

  • The patent's life is 20 years from filing, assuming it was filed within the statutory period.
  • Patent term adjustments or extensions are rare in Mexico, especially for pharmaceuticals.

Strategic Positioning

Protection Strengths

  • If claims are broad, they could block competitors from similar compounds or formulations.
  • Synthesis and formulation claims bolster protection for manufacturing.

Vulnerabilities

  • Narrow claims limit enforceability.
  • Prior art disclosures of similar compounds or methods weaken validity prospects.

Potential Challenges

  • Invalidity due to prior art or obviousness.
  • Patent opposition or nullity challenges within the Mexican Institute of Industrial Property (IMPI).

Cross-Licensing and Litigation

  • Patent holders may seek licensing deals or enforce their rights through litigation if production infringes claims.

Concluding Insights
MX2021014126 provides a focused protection scope, primarily around a specific compound or therapeutic method. Its patent landscape overlaps with global filings, with Mexico serving as a strategic market for regional exclusivity. Protectability hinges on claim breadth, prior art navigation, and enforcement.


Key Takeaways

  • The patent covers a specific chemical or therapeutic claim, with scope determined by the claim language's breadth.
  • The Mexican patent landscape aligns with international standards, emphasizing novelty and inventive step.
  • Patent protection spans 20 years, with strategic considerations for claim scope and prior art challenges.
  • Competitor activity in this space involves multiple jurisdictions, affecting Mexican patent enforceability.
  • Effective patent strategies combine comprehensive claims, active monitoring of the landscape, and enforcement capacity.

Frequently Asked Questions

1. How does MX2021014126 compare to similar patents globally?
It likely aligns with international patents covering similar compounds or uses but depends on claim scope and prior art. Global filings may include equivalents in the US, EU, or China.

2. Can the patent be challenged in Mexico?
Yes. Third parties can file opposition within the Mexican patent office or initiate nullity proceedings if they prove lack of novelty or inventive step.

3. What protections are essential for maintaining the patent's strength?
Broad claims, detailed description, and strategic claim amendments during prosecution ensure enforceability and defend against invalidation.

4. How does patent landscape affect commercialization?
Existing patents in other jurisdictions influence market entry strategies and licensing negotiations within Mexico.

5. What are the risks associated with patent infringement?
Infringement may lead to lawsuits, damages, and injunctions, particularly if the patent claims are broad and enforceable.


References

[1] Mexican Institute of Industrial Property (IMPI). (2020). Guidelines on Patent Examination in Mexico.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.